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Abstract
Background: Polybrominated diphenyl ethers (PBDEs) are flame retardants used widely and in increasing amounts
in the U.S. over the last few decades. PBDEs and their metabolites cross the placenta and studies in rodents
demonstrate neurodevelopmental toxicity from prenatal exposures. PBDE exposures occur both via breastfeeding
and hand-to-mouth activities in small children.
Methods: Participants were 100 children from the CHARGE (CHildhood Autism Risk from Genetics and the
Environment) Study, a case-control epidemiologic investigation of children with autism/autism spectrum disorder,
with developmental delay and from the general population. Diagnoses of autism were confirmed by the Autism
Diagnostic Observation Schedule and Autism Diagnostic Inventory-Revised, and of developmental delay using the
Mullen’s Scales of Early Learning and the Vineland Adaptive Behavior Scales. Typically developing controls were
those with no evidence of delay, autism, or autism spectrum disorder. Eleven PBDE congeners were measured by
gas chromatography/mass spectrometry from serum specimens collected after children were assessed. Logistic
regression was used to evaluate the association between plasma PBDEs and autism.
Results: Children with autism/autism spectrum disorder and developmental delay were similar to typically
developing controls for all PBDE congeners, but levels were high for all three groups.
Conclusions: Plasma samples collected post-diagnosis in this study may not represent early life exposures due to
changes in diet and introduction of new household products containing PBDEs. Studies with direct measurements
of prenatal or infant exposures are needed to assess the possible causal role for these compounds in autism
spectrum disorders.
Background
Few studies of autism have addressed environmental
pollutants, and little research has been conducted in
humans to assess neurodevelopmental toxicity of bromi-
nated flame retardants. Polybrominated diphenyl ethers
(PBDEs) are flame retardants used widely in carpeting,
foam furniture and car seats, textiles, plastic casings for
television sets and computers, household appliances,
and construction materials. The foam products have
contained primarily penta-BDEs; plastic casings on small
appliances and computers have been primarily octa-
BDEs; and television sets, electrical wiring, and backings
on draperies have generally been deca-BDEs [1]. Levels
of PBDEs in human breast milk rose rapidly for several
decades in Sweden but then declined, most probably in
response to regulatory actions [2]. Concentrations
reported in human blood are consistently higher in the
U.S. than in Europe [3,4] and recent reports suggest
that body burdens in California are among the highest
worldwide [5-7]. Food, dust and air are the main routes
of exposure [4,8].
P B D E sc r o s st h ep l a c e n t aa n da r em o b i l i z e di n t o
breast milk during lactation [9,10]. A body of evidence
has accumulated from experimental animal studies
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lowing prenatal and early life exposures [11-14]. These
include hyperactivity and permanent alterations in spon-
taneous behaviors, deficits in learning and memory, and
failure to habituate to novel stimuli, with effects seen at
exposure levels comparable to those observed in
humans [14]. In mice, exposures on postnatal days 3
and 10, but not postnatal day 19 altered motor beha-
viors, suggesting specific windows of vulnerability that
translate to prenatal periods in humans [12].
Possible mechanisms relevant to neurodevelopmental
toxicity include disruption of thyroid hormone or sex
steroid homeostasis during the prenatal period [15-18],
a period in which these systems play critical roles in
fetal development, particularly in the formation of the
external granule cell layer of the cerebellum [18]. PBDEs
also show evidence of immunotoxic effects in rodent
experiments [19]. Meanwhile, increasing research sug-
gests neuroimmune pathways could contribute to autism
[20,21]. In mechanistic studies, PBDEs also disregulate
neuronal Ca
2+ signaling events [22,23], effects that
appear to be magnified by hydroxylation of parent struc-
t u r ea n dt h a tp r e d i c tn e u r o t o x ic potential [22,24]. Sev-
eral genes associated with autism risk are tightly
regulated by Ca
2+ (e.g., neuroligin-3 [25]), or are them-
selves regulators of cellular Ca
2+ signals (e.g., Timothy
Syndrome). Several congeners activate the pregnane X
receptor, resulting in induction of cytochrome P450
enzymes [26].
Evidence of neurodevelopmental toxicity from prenatal
exposures in animals, together with the abilities of
PBDEs to disrupt endocrine systems and to interfere
with immune development, provided the rationale for
this pilot study of PBDEs and autism. This investigation
builds on the Childhood Autism Risk from Genetics and
the Environment (CHARGE) Study, which was initiated
i n2 0 0 2a sp a r to ft h eC e n t e rf o rC h i l d r e n ’sE n v i r o n -
mental Health at the University of California, Davis. Its
overall goal, and that of the Center for Children’s Envir-
onmental Health in general, is to identify factors that
influence the incidence and severity of autism. We
therefore compared levels of several PBDE congeners in
cases to those in typically developing (TD) controls.
Elsewhere, we reported that concentrations of PBDEs in
this study are among the highest yet reported anywhere
in the world [5].
Methods
Study design
This pilot project was designed to utilize the ongoing
CHARGE Study, a comprehensive epidemiologic investi-
gation of environmental factors in the etiology of aut-
ism. Launched in 2003, the CHARGE Study has
enrolled well over 1000 children with the primary goal
of identifying causes and contributing factors for autism,
focusing especially on the chemical environment [27]. In
addition, the CHARGE Study seeks to evaluate gene ×
environment interactions and to analyze phenotypic
subtypes defined using behavioral or physiologic criteria,
in order to determine whether environmental factors are
more strongly related to specific subsets of autism cases.
The CHARGE Study uses a case-control design, enrol-
ling families with an index child from one of three
groups: children with autism, children with developmen-
tal delay but not autism, and children from the general
population. All index children are between two and five
years of age, reside in the study catchment area, were
born in California, and are living with a biological par-
ent who speaks either English or Spanish. The general
population sample serves as a referent or control group.
Recruitment and Data Collection
CHARGE Study recruitment of families with children in
the autism/autism spectrum (AU/ASD) and develop-
mental delay (DD) groups is largely through the Califor-
nia Department of Developmental Services (DDS)
system, and through general publicity and other studies
at the UC Davis M.I.N.D. (Medical Investigation of Neu-
rodevelopmental Disorders) Institute. Population-based
controls are selected by stratified random sampling from
State birth files, with probabilities aimed at representing
the overall distribution of autism cases with regard to
age, gender, and broad geographic area of residence.
Based on information in the birth record (for general
population controls) or the DDS record (for the autism
and DD groups), CHARGE Study staff search to locate
the families and invite them to join the study.
All families are seen at the M.I.N.D. Institute where
informed consent is administered and the child has
a full psychometric evaluation and medical examination.
We evaluate children with autism using the Autism
Diagnostic Observation Schedules (ADOS) and interview
the primary caregiver using the Autism Diagnostic
Interview-revised (ADI-R); scores on these two instru-
ments are used to confirm an autism or autism spec-
trum disorder diagnosis. A final diagnosis of autism
(AU) is defined as meeting criteria on the communica-
tion, social, and repetitive behavior domains of the ADI-
R with onset prior to 36 months and scoring at or
above the communication and social interaction total
cut off for autistic disorder on the ADOS module one
or two. Children classified with autism spectrum disor-
ders (ASD) are those who do not fully satisfy the criteria
for autism but who do meet criteria on either the
communication or the social interaction domain of
the ADI-R prior to 36 months, are within two points of
the cut-off on the other domain, and are above the
social and communication total cutoff for ASD on the
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were combined into one group (AU/ASD) for statistical
analysis of this pilot study. For children from the other
two groups, the Social Communication Questionnaire
(SCQ) is administered and if the score is above 14, the
ADI-R and ADOS are administered to determine the
final diagnosis for the CHARGE Study classification.
Developmental delay is broadly defined as having a Mul-
len Scales of Early Learning (MSEL) Composite Score of
less than 70, a Vineland Adaptive Behavior Scales
(VABS) Composite of less than 70, and scoring above
14 on the SCQ. For this analysis, the delayed group also
included children recruited from the DDS system who
received services based on a diagnosis of developmental
delay, had composite scores above the cutoffs and did
not meet criteria for AU/ASD, as well as two children
recruited from the general population with clear deficits
on the MSEL (60 or lower). The typical development
(TD) classification comprises children from the general
population whose Composite scores on the MSEL and
VABS were at or above 70. We categorized developmen-
tal regression status in children with autism using the
ADI-R and the Early Development Questionnaire
(EDQ). Regression versus early onset status was defined
as loss of either language or social skills using ADI-R
and EDQ questions [28].
Information on potential sociodemographic or envir-
onmental confounders was obtained from the birth cer-
tificate and from an extensive telephone interview with
the primary caregiver. The interviewers were kept blind
to the case status of the family as much as possible.
Finally, biologic specimens were collected, including
whole blood, which was drawn into yellow top acid
citrate dextrose tubes and centrifuged. Plasma was
stored at -80 degrees C for later analysis. Further details
about recruitment and data collection in the CHARGE
Study have been previously published [27]. All protocols
were approved by the UC Davis School of Medicine and
State of California Institutional Review Boards; data and
specimens were collected only after informed consent
was obtained.
Pilot Sample
In the first funding period of the CHARGE Study (2001-
2006), 799 children and their families participated. From
these, we selected 100 children with blood samples col-
lected from June 2003 to September 2005, in which suf-
ficient volume of plasma was available. These were
selected by stratified random sampling within strata of
case groups: 50 children who entered the study with
a diagnosis of autism, 25 with developmental delay and
25 from the general population. After clinical assess-
ments and application of diagnostic criteria, the final
study groups were: AU/ASD, n = 51, of whom 23
showed regression and the remaining 28 were categor-
ized as early onset; developmentally delayed, n = 26; and
typical development, n = 23.
Laboratory methods for PBDE quantitation
Vials of serum (2-3 ml) were shipped to Sweden for
chemical analysis of PBDEs. Samples were extracted and
analyzed using gas chromatography with mass spectro-
metry. The extraction and cleanup procedure is
described elsewhere [29]. Briefly, the surrogate standards
( S S ) ,B D E - 7 7( 0 . 5n g )a n d
13C - B D E - 2 0 9( 1n g )w e r e
added to 2-3 ml of plasma prior to extraction. The
extracts were evaporated, and resolved in hexane. The
neutral and phenolic substances were separated with
potassium hydroxide (0.5 M in 50% EtOH) and hexane
partitioning. The bulk of lipid in the neutral fraction
was removed with concentrated sulfuric acid treatment.
Additional cleanup was then preformed on a silica:sulfu-
ric acid column (0.9 g). The silica gel column was
always washed prior to sample application with the
same solvent as the analytes were to be eluted with. The
neutral fraction was fractionated on a column of acti-
vated silica gel (0.7 g). Most of the PCB congener and
major conventional organochlorine pesticide interfer-
ences were eluted with hexane (3 ml) and the PBDEs
were eluted with dichloromethane (8 ml). The solvent in
the PBDE fraction was changed to hexane and reduced
to 100 μlp r i o rt oG C / M Sa n a l y s i s .A l ls a m p l e sw e r e
p r o t e c t e df r o md a y l i g h td u r i n gh a n d l i n ga n ds t o r a g et o
prevent photochemical degradation of the brominated
compounds to be analyzed.
Chemical standards were synthesized in-house for the
individual congeners analyzed in this study, while BDE-
209 was purchased from Fluka Chemie Buchs, Switzer-
land and
13C-labeled BDE-209 from Cambridge Isotope
Laboratories, Andover, MA. All solvents were of pesti-
cide quality. 2-Propanol from AnalaR (BDH laboratory
supplies pool, England) and methyl tert-butyl ether
(HPLC-grade; Rathburn, Walkerburn, Scotland) were
glass-distilled prior to use. Silica gel (<0.063 mm) was
purchased from Merck (Darmstadt, Germany) and acti-
vated at 300°C overnight, before it was used.
The PBDE analysis was performed by gas chromato-
graphy/mass spectrometry (GC/MS) utilising a Finnigan
SSQ 700 instrument (ThermoFinnigan, Bremen, Germany)
connected to a Varian 3400 gas chromatograph equipped
with a CTC A200S autosampler. All instrumentation
settings are reported elsewhere [2]. The PBDE conge-
ners were analyzed with selected ion monitoring (SIM)
by scanning for the negative bromide ion (isotopes m/z
79 and 81), formed by electron capture reactions at che-
mical ionization (ECNI) with methane (5.0, AGA,
Stockholm, Sweden) as the electron thermalization buf-
fer gas at 5.6 torr and a primary electron energy of 70
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ECNI was used by monitoring m/z 484.2 and 486.2 for
12C-BDE-209 and m/z 494.2 and 496.2 for
13C-BDE-209
[30]. All chromatographic data were collected, analyzed,
and quantified using the proprietary ICIS2 software
from Thermofinnigan.
Eleven PBDE congeners, BDE-28, BDE-47, BDE-66,
BDE-85, BDE-99, BDE-100, BDE-153, BDE-183, BDE-
197, BDE-207 and BDE-209, were analyzed with GC/MS
(ECNI), as specified above, and quantified with the sur-
rogate standards, BDE-77 and
13C-BDE-209. BDE-154
could not be quantified alone due to co-elution of the
2,2’,4,4’,5,5’-hexabromobiphenyl (BB-153) known to be
present in human serum samples. Procedure solvent
blank samples representing every seventh sample were
analyzed in the same way as the serum extracts Limits
of quantification (LOQs) were defined in direct relation
to the amount of interference of PBDEs in the blank
samples. The PBDEs in the samples had to be 3 times
the concentration of the PBDEs in the blank to be con-
sidered for quantification. The LOQs were: for BDE-47,
0.03 ng, for BDE-207, 0.015 ng, for BDE-209, 0.01 ng;
all other BDE congeners analyzed had LOQ values
below 0.006 ng. In this study the LOQ values were set
in direct relation to the amount of the PBDEs measured
in the blank samples. The average blank sample amount
has been subtracted from the results. Laboratory refer-
ence material was run in parallel to the analyzed
samples.
We examined each BDE congener separately, and cal-
culated several sums on a molar basis to take account
variability in molecular weights. Because of low concen-
trations for BDE-183, only 64 samples yielded values
above the limits of detection. For this reason, we calcu-
lated the sum of the seven measured lower brominated
congeners from BDE-28 through BDE-153, and sepa-
rately, the three measured octa- and deca-BDEs (BDE-
197, -207, and -209).
Lipids
Serum triglycerides and cholesterols were measured at
the UC Davis clinical chemistry laboratory and total
serum lipids were estimated [31]. Only 94 specimens
have lipid values: two in the AU/ASD group, two in the
DD group, and two in the TD group had insufficient
sample volume for lipid determinations. Because PBDEs
are lipophilic, concentrations are presented both on
a wet weight basis (ng PBDEs/ml serum) and on a lipid
basis (ng PBDEs/g lipids and pmol PBDEs/g lipids).
Data Analysis
Laboratory data were received and merged with
CHARGE Study files containing diagnostic and covariate
information. All data were cleaned and verified,
univariate distributions were reviewed for plausibility
and consistency checks were performed. A log-transfor-
mation was applied to all individual BDE congeners and
their sums due to the skewed distributions, as typically
occurs with environmental contaminants.
To prepare for a multivariate analysis, we screened
potential confounders. Our goal was to balance the need
for a parsimonious model due to the small sample size
in this pilot project with the importance of controlling
actual confounding variables. Candidate confounders
included mother’s education and age at delivery, father’s
age, type of insurance payment for the delivery, number
of computers in the household (as a measure of socioe-
conomic status), and child’sa g e ,s e x ,e t h n i c i t y ,B M I ,
calendar time, and consumption of ocean fish. Those
covariates showing associations with both PBDEs and
case status were considered for inclusion in the multi-
variate analysis. Redundancy was assessed and a smaller
set of variables was selected.
In the final analyses, we fit unconditional multivariate
multinomial logistic regression models predicting the
odds of autism or developmental delay relative to typical
development as a function of PBDE concentrations with
control for maternal education and calendar time. We
calculated 90% confidence intervals, in recognition of
the exploratory nature of this project. Analyses were
weighted to reflect the socioeconomic distribution of
the three target populations, i.e., children with autism,
with developmental delay, or from the general popula-
tion. Additional logistic regression models were fit to
predict regressive AU vs. TD, and early onset AU vs.
TD. As an exploratory analysis, we also subdivided the
AU/ASD children by language development based on
t h ec r i t e r i au s e df o rt h ec h o i c eo ft h eA D O Sm o d u l e
(i.e. nonverbal if module 1, verbal if module 2), to evaluate
the association of PBDEs with these subtypes. ADOS
Module 1 is intended for children who have limited use or
understanding of words or for those who do not consis-
tently use phrases of two or more words. Module 2 is
administered to children who use some phrases and syntax
consistently.
Results
Population Characteristics
Table 1 shows the characteristics of the study popula-
tion. Three factors distinguished children with AU/ASD
from typically developing children: maternal education,
maternal age, and calendar date of blood draw. The
mothers of children with AU/ASD were more likely
than the mothers from either the DD or typically devel-
oping children to have had some college education (p =
0.03), while mothers of the DD children were the most
likely to have had no education beyond high school.
Additionally, mothers of AU/ASD, but not DD children,
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ment of autism cases began before recruitment from the
other groups, resulting in significant differences in
calendar time at blood draw. The deliveries of children
with DD were somewhat less likely to be covered by pri-
vate health insurance than deliveries of children in the
other two groups, although the difference was not statis-
tically significant.
The children with autism were less likely to eat ocean
fish (primarily tuna), but in this small sample, the differ-
ences were neither large nor statistically precise. With
regard to mercury as a confounder, children with
Table 1 Characteristics of study sample (n = 94) by diagnostic status in the CHARGE Study, California, 2003 - 2005
AU/ASD DD N = 24 TD n = 21
Characteristic: Categorical variables: Weighted
(unweighted) %†
Weighted
(unweighted) %†
Weighted
(unweighted) %†
AU/ASD vs. TD
p-value†
DD vs. TD
p-value†
Child’s sex, male 92 (88) 68 (63) 86 (86) 0.81 0.19
Child’s race/ethnicity
White 30 (43) 18 (29) 32 (43) 0.94 0.56
Hispanic 45 (43) 60 (50) 48 (43)
Other 25 (14) 22 (21) 20 (14)
Mother’s education
≤ High school 12 (10) 44 (33) 36 (28) 0.03 0.10
Some college 60 (51) 45 (46) 26 (24)
College or higher degree 28 (39) 11 (21) 38 (48)
Computers in household
None 13 (9) 37 (29) 24 (20) 0.61 0.35
One 52 (52) 24 (25) 47 (50)
Two or more 35 (39) 39 (46) 29 (30)
New car purchased in the first 2 years of child’s
life
21 (22) 24 (30) 10 (10) 0.29 0.24
Private insurance provider‡ 72 (80) 50 (67) 74 (86) 0.88 0.17
Regional Center catchment area‡
Alta, Far Northern, Redwood Coast 28 (31) 51 (54) 29 (29) 0.46 0.63
North Bay 20 (23) 5 (4) 11 (14)
East Bay, San Andreas, Golden Gate 16 (10) 7 (8) 5 (10)
Valley Mountain, Central Valley, Kern 18 (18) 17 (13) 34 (33)
LA RCs*, Orange, San Diego, Tri-counties,
Inland, San Gabriel/Pomona
18 (18) 20 (21) 21 (14)
Child ate ocean fish (incl. tuna, caught) prior to
age 2 yrs
27 (27) 39 (37) 39 (43) 0.37 0.99
Child ate freshwater fish (incl. caught) prior to
age 2 yrs
8 (7) 7 (8) 8 (9) 0.99 0.85
Child’s age, yrs 3.7 (0.1) 3.7 (0.2) 3.7 (0.1) 0.99 0.99
Child’s weight, kg 17.1 (0.6) 15.4 (0.9) 16.9 (0.8) 0.85 0.23
Child’s height, cm 99.5 (1.4) 96.4 (1.9) 99.2 (1.6) 0.90 0.26
Child’s weight-to-height ratio, kg/m 16.9 (0.4) 15.8 (0.7) 16.9 (0.6) 0.92 0.25
Child’s body mass index (BMI) 16.9 (0.2) 16.3 (0.6) 17.0 (0.5) 0.87 0.39
Length of breastfeeding, months 5.7 (0.6) 6.1 (1.7) 6.2 (1.9) 0.81 0.98
Mother’s age, yr‡ 30.4 (0.8) 28.3 (1.5) 27.7 (1.4) 0.10 0.79
Father’s age, yr‡ 32.5 (1.0) 30.7 (2.3) 30.4 (1.5) 0.25 0.92
Calendar years from first participant blood draw 1.0 (0.1) 1.2 (0.1) 1.4 (0.1) 0.006 0.34
†The weights were calculated to reflect the population targeted for recruitment. For children with AU/ASD or DD, this population was identified from the
California DDS records for those who met our geographic and age criteria during the recruitment period. For children in the TD group, they were identified from
State Birth Files, after restricting to those who met our geographic and age criteria during the recruitment period. The p-values were from comparisons of
weighted proportions.
‡At the time of the child’s birth.
*Los Angeles Regional Centers include Lanterman, Harbor, Westside, and Eastern, South Central, and North Los Angles.
Hertz-Picciotto et al. Environmental Health 2011, 10:1
http://www.ehjournal.net/content/10/1/1
Page 5 of 11AU/ASD had similar levels of blood mercury. Moreover,
blood Hg was not correlated with any of the PBDEs:
Pearson correlation coefficients (with all variables log-
transformed) ranged from -0.21 to 0.09. There were no
significant differences across diagnostic groups with
regard to father’sa g e ,o rc h i l d ’s age, sex, race/ethnicity,
region of California, height, weight, BMI, duration of
breastfeeding, or consumption of freshwater fish.
PBDE Concentrations
In unadjusted analyses, no individual PBDE congener
(figures 1 and 2) or group of congeners (figure 2) dif-
fered comparing TD children with children having
a confirmed AU/ASD diagnosis. A tendency towards
higher concentrations of the low brominated congeners
and lower concentrations of the more highly brominated
PBDEs was observed among DD children (figure 1), but
these were not significant. The distribution of PBDE
congeners by diagnostic group is shown numerically in
Additional file 1: Supplemental Table 1a (ng/g plasma),
1b (ng/g lipid), and 1c (pmol/g lipid).
Factors predictive of at least one PBDE congener were
child’s age, child’s sex, maternal age, maternal education,
duration of breastfeeding, and calendar time, and a few
other socioeconomic variables. The only factors that
could confound the PBDE × AU/ASD associations,
based on their relationships to both PBDEs and child
development, were maternal age and education, and for
developmental delay, private insurance. Because of high
correlations among maternal education, maternal age,
and insurance status, we adjusted only for maternal edu-
cation in the multivariate analyses. We also chose to
include calendar year as a design variable that was
strongly related to outcome. Additional adjustment for
child’s age, sex, or consumption of ocean fish, the type
of health insurance used for the delivery hospitalization,
as well as number of computers or other children in the
household left results for PBDEs essentially unchanged.
After adjustment for maternal education and calendar
time, children with autism still showed no significant
differences in their serum PBDE concentrations relative
to children with typical development, though in general,
the levels were slightly lower (table 2). Comparing the
75
th vs. 25
th percentiles of PBDE levels, odds ratios for
the AU/ASD group ranged from 0.49 (BDE #153, p =
0.12) and 0.50 (BDE #85, p = 0.11) to 0.87 (BDE #183,
p = 0.66), and in all instances, the 90% confidence inter-
vals easily overlapped the null value of 1.0. Odds ratios
for DD vs. TD were above 1.0 for congeners with fewer
than 8 bromines, and were below 1.0 for octa- through
deca-BDEs, but again, all confidence intervals easily
included the null. Only the odds ratio for BDE #197
(0.48) approached significance (p = 0.10).
Phenotypic Subsets of Autism
In further analyses, we separated the early onset from
regressive cases of autism. The two subtypes were simi-
lar in their distributions of PBDEs, and in multivariate-
Figure 1 Congener-specific PBDEs (ng/g lipids) by diagnostic group, children 24-60 months old, California, 2003-2005.I n d i v i d u a l
congener distributions are shown on the log scale for PBDEs in ng/g lipids, measured in plasma taken from children participating in the
CHARGE Study (n = 94). Differences among the three groups (AU/ASD, pink; DD, tan; TD, green), are minimal. All measurements were made in
blood samples collected after the diagnosis.
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Page 6 of 11Figure 2 Congener-specific PBDEs (molar basis: pmol/g lipid) and selected sums by diagnostic group, CHARGE Study children 24-60
months old, California, 2003-2005. Congener distributions are shown on the log scale for PBDEs in pmol/g lipids, and sums of the lower
brominated, higher brominated, or total measured PBDEs are also shown. Measurements were in plasma taken from children participating in the
CHARGE Study (n = 94). Differences among the three groups (AU/ASD, pink; DD, tan; TD, green), are minimal. All measurements were made in
blood samples collected after the diagnosis.
Table 2 Multivariate models* predicting AU/ASD and DD the CHARGE Study, 2003-2005
Plasma Concentration**
ln (ng/g lipid) ln (pmol/g lipid) AU/ASD vs. TD DD vs. TD
Predictor variable (25
th,7 5
th) (25
th,7 5
th) b SE OR† 90% CI p-value b SE OR† 90% CI p-value
BDE 28 (-0.47, 0.70) (0.43, 1.60) -0.17 0.38 0.82 (0.39, 1.71) 0.66 0.34 0.49 1.48 (0.58, 3.82) 0.49
BDE 47 (3.56, 4.75) (4.28, 5.47) -0.24 0.32 0.75 (0.40, 1.42) 0.46 0.35 0.44 1.52 (0.65, 3.58) 0.42
BDE 66 (-1.41, -0.11) (-0.69, 0.61) -0.39 0.38 0.60 (0.27, 1.36) 0.30 0.48 0.42 1.86 (0.76, 4.59) 0.26
BDE 85 (0.53, 1.91) (1.10, 2.48) -0.50 0.31 0.50 (0.25, 1.02) 0.11 0.32 0.39 1.55 (0.64, 3.77) 0.42
BDE 99 (2.57, 3.90) (3.14, 4.47) -0.33 0.32 0.65 (0.32, 1.31) 0.31 0.46 0.38 1.84 (0.80, 4.25) 0.23
BDE 100 (2.61, 3.68) (3.18, 4.25) -0.32 0.31 0.71 (0.41, 1.23) 0.31 0.41 0.43 1.55 (0.72, 3.34) 0.34
BDE 153 (2.47, 3.61) (2.91, 4.05) -0.63 0.41 0.49 (0.23, 1.05) 0.12 0.61 0.48 1.99 (0.81, 4.91) 0.21
BDE 183 (-0.77, -0.18) (-0.44, 0.15) -0.25 0.56 0.87 (0.50, 1.49) 0.66 0.05 0.53 1.03 (0.62, 1.72) 0.92
Σ BDE 28 - 153 - (5.08, 6.10) -0.34 0.37 0.71 (0.38, 1.32) 0.36 0.51 0.46 1.69 (0.78, 3.65) 0.26
Σ BDE 28 - 183 - (5.11, 6.10) -0.34 0.38 0.71 (0.38, 1.33) 0.37 0.52 0.46 1.67 (0.78, 3.58) 0.26
BDE 197 (-0.35, 0.81) (-0.13, 1.04) -0.44 0.39 0.60 (0.28, 1.26) 0.25 -0.63 0.39 0.48 (0.23, 1.00) 0.10
BDE 207 (0.50, 1.00) (0.63, 1.13) -0.42 0.55 0.81 (0.51, 1.28) 0.45 -0.86 0.60 0.65 (0.40, 1.07) 0.15
BDE 209 (0.53, 1.58) (0.57, 1.62) -0.42 0.42 0.65 (0.31, 1.34) 0.32 -0.49 0.46 0.60 (0.27, 1.32) 0.29
Σ BDE 197 - 209 - (1.61, 2.44) -0.51 0.52 0.65 (0.32, 1.34) 0.33 -0.76 0.56 0.53 (0.25, 1.15) 0.18
Σ BDE 28 - 209 - (5.15, 6.12) -0.35 0.39 0.71 (0.38, 1.33) 0.37 0.51 0.47 1.64 (0.77, 3.50) 0.28
Mother’s education‡
≤ high school - - -0.60 0.85 0.55 (0.13, 2.23) 0.48 1.50 0.87 4.49 (1.07, 18.90) 0.09
some college - - 1.10 0.73 3.01 (0.90, 10.01) 0.13 1.75 0.86 5.75 (1.40, 23.59) 0.04
Calendar time‡ - - -1.11 0.55 0.33 (0.13, 0.81) 0.04 -0.67 0.68 0.51 (0.17, 1.56) 0.32
*Each congener or subset of congeners was entered, log-transformed and lipid-adjusted, into a separate multinomial logistic regression model to predict AU/ASD
or DD.
** Percentiles are presented as log-transformed values of concentrations in lipids.
† Odds ratio for difference in PBDE levels comparing those at 75
th and 25
th percentiles.
‡All models were fitted with multivariate adjustment for mother’s education (reference group is college degree) and calendar time, and the results for these
factors were similar across models. What we present in the table was a model with mother’s education and calendar time without PBDE.
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trols for any PBDE or group of PBDEs (data not
shown). Alternative analyses dividing the case group by
language development and controlling for child’sa g e ,
a strong predictor of verbal skills, yielded no evidence of
differences in PBDEs as compared with TD controls.
Discussion
As previously described, PBDEs are widespread in
household products and have now moved into the food
chain [5], although little research has addressed human
health effects. The lack of association between children’s
circulating levels of PBDEs and autism case status does
not preclude a role for PBDEs in autism etiology. A
weakness in this pilot study was the examination of cur-
rent levels of PBDEs as a proxy for exposures that pre-
ceded the neuropathologic changes leading to autism. In
retrospective research such as the CHARGE Study and
other case-control investigations, obtaining etiologically
relevant exposure measurements is challenging. Half-
lives of PBDEs vary. Higher brominated compounds
appear to have the shortest half-lives, e.g., 15 days for
#209, 39 days for #207, and 94 days for #183, based on
a study involving occupational exposures [32] and there-
fore, correlations of internal measurements over a per-
iod of years would not be expected to be high. Half-lives
of lower brominated congeners were estimated based on
d a i l yi n t a k ea n dt o t a lb o d yb u r d e na s1 . 8 ,2 . 9 ,1 . 6 ,a n d
6.5 years for BDE-47, -99, -100, and -153, respectively
[33]. Nevertheless, even for those compounds that are
retained, correlations over time can vary widely and will
be a function primarily of the introduction of new
sources, elimination of old sources, and changes in
behaviors that influence extent of contact with those
sources. The correlation between current and past expo-
sure will be greatest when the sources are constant over
time for an individual, or when external sources have
been eliminated and only past exposures are present,
with gradual ongoing excretion. Exposures were rising
in the U.S. between the births and the time of data col-
lection for these subjects, as a result of continued pro-
duction of household furnishings and electronics with
PBDEs, and increasing levels in the food supply, and
therefore, it is unlikely participants’ exposures remained
steady [3]. We also note that the concentrations in this
sample are, to our knowledge, higher than previously
reported in any other population, even from the 2003-
2004 NHANES sample [34], and are seven to ten times
higher than those reported to predict lower cognitive
scores in a sample of children from New York City [35].
During the prenatal period, the mother’se x p o s u r e s
will be critical. Her exposures will be partially based on
diet, and partially based on pathways related to the
home environment, including inhalation of both
chemicals in the gas phase and resuspended particulate
matter, as well as dermal exposure and non-dietary
ingestion of dust. During early infancy, exposures, parti-
cularly for lower brominated congeners [36] appear to
be primarily through breast milk [8], again reflective of
the mother’s exposure, or infant formula, as well as
some contribution from inhalation of air and dust, pos-
sibly from mattresses, upholstered furniture, and cush-
ions. With the introduction of solid food, the diet
becomes more varied, with new sources of PBDE expo-
sures, even though some toddlers choose to eat a lim-
ited number of food items. As children start to interact
more independently with their environment toward the
second half of the first year, intake becomes increasingly
influenced by what is present in the home environment,
in large part due to increases in frequency of contact
with surfaces, hand to mouth activity, and object to
mouth activity [37,38]. Higher concentrations have been
found in toddlers than in school-age children or adults,
supporting a critical role for non-food ingestion during
the early years [36]. All of these factors underscore the
differences between exposures measured at 24 to 60
months of age versus those that occurred during a criti-
cal time period, which may very well be the prenatal
period. The issue is further complicated when compar-
ing children with developmental disorders to those with
typical development: the former may have different tim-
ing or frequency in their hand to mouth activity, delays
in explorative play, or a more limited diet due to feed-
ing difficulties [39-41]. Similar to what others have
reported, in our study sample, both food and non-food
sources appeared to contribute to the children’s body
burdens [5].
Given the uncertainties outlined above regarding
exposure and intake, particularly for infants and tod-
dlers, and the dramatic changes between birth and age
two-five years in diet and play behaviors, current PBDE
concentrations (even when half-lives are long, e.g.,
4 years) may not adequately estimate exposures in the
prenatal or early postnatal period. House dust or banked
specimens from adults (whose diet and behaviors change
less than their children’s) might provide better estimates
of PBDE exposures during the critical time windows.
Breakdown of the deca-BDE (209) may occur in house
dust, but for other congeners, stability of levels in house
dust may be an indication that it serves as a more valid
repository of long-term exposures than blood plasma, at
least in young children [42].
Although few risk factors have been established for
autism, we evaluated more than ten potential confoun-
ders that had no appreciable effect on the coefficients
relating PBDEs to diagnosis. Similar to the findings at
an older age [43], during the first two years of life, chil-
dren with autism were less likely to eat ocean fish
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were neither large nor statistically precise. As Hg was
not associated with case status and showed low correla-
tions with PBDEs, it could not have confounded the
analyses of PBDEs and AU/ASD or developmental delay.
Confounding by known risk factors or other sociodemo-
graphic characteristics seems unlikely to have been
responsible for the null results of this study.
Another consideration in the interpretation of these
null findings is that the levels of PBDEs may be suffi-
ciently high that all children who are predisposed to
develop autism have had exposures sufficient to surpass
their individual thresholds. It has previously been noted
[44] that when exposure is high and ubiquitous, no
study will be able to detect the effect of that exposure;
within such populations, diseases will instead appear to
have only genetic influences. Despite the speculative
nature of this proposition in the case of autism and
PBDEs, the problem of widespread environmental che-
mical pollution poses a serious obstacle to identifying
health effects. Even their interaction with genes will be
elusive and research could appear to support a purely
genetic etiology either when the exposure variability is
low, or when levels are so high as to exceed the thresh-
old in all susceptible individuals.
The lower concentration of BDE #197 in children with
developmental delay is most likely a chance finding,
given the small sample size in this pilot study and the
large number of comparisons made. Children with
developmental delay often have more, rather than less,
hand-to-mouth activity, thus it is unclear whether beha-
viors could explain this particular association. For the
lower brominated congeners, the more extreme values
in some children from the DD group is interesting, and
might reflect different behavioral patterns in children
with cognitive and adaptive impairments.
Thus, although our current measurements of PBDEs
do not predict risk of autism, this pilot project should
not be construed as the last word on PBDEs and autism.
On the one hand, our null findings could have been the
consequence of substantial misclassification relative to
exposure in the etiologically critical time windows: mea-
surements in plasma samples collected at least a year
and potentially as much as five years after the key events
in neurodevelopment may have been poor approxima-
tions of the relevant prenatal or early postnatal expo-
sures. On the other, the biological plausibility of a
causal association between prenatal or early postnatal
PBDE exposures and the development of autism is sup-
ported by numerous documented toxicologic mechan-
isms relevant to CNS development.
Further research can be directed towards several
issues: a better understanding of sources and pathways
of exposure for pregnant women and young children;
design of methods to obtain more accurate measure-
ments of exposure, especially to hydroxylated metabo-
lites, during periods critical for autism etiology; analysis
of larger sample sizes; and expansion of animal and in
vitro models of neurodevelopmental toxicity to define
the molecular mechanisms. Of potential relevance are
Ca
2+ signaling pathways, endocrine disruption, or other
cellular, intracellular and transport processes, and their
regulation by genes that may have been associated with
autism.
Conclusions
Although this study found no association between chil-
dren’s circulating levels of PBDEs and autism case sta-
tus, further work investigating a role for PBDEs in
autism etiology is warranted for several reasons: expo-
sures in the U.S. remain high; data from animals [11,14]
and humans [35] have shown neurodevelopmental
effects following prenatal exposures; and experimental
research suggests several relevant mechanisms of toxi-
city [15,22-25]. The underlying assumption of the ana-
lyses presented here was that PBDEs in children 24-60
months could serve as a proxy for exposures that pre-
ceded the neuropathologic changes leading to autism,
e.g., in prenatal or early postnatal life. Recent reports
[5,8,45], indicate that diet may contribute substantially
to children’s PBDE concentrations. Given that major
dietary changes occur during the first few years of life,
and that maternal pregnancy food consumption may be
quite dissimilar from children’s intake in their third to
fifth year of life, it seems probable that exposure was
misclassified. Future research should seek other methods
to obtain etiologically relevant measurements of PBDE
exposures in case-control studies, and opportunities to
assess these compounds in prospective investigations
of ASD.
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